Make faster, better, drug development decisions
We understand the critical importance of precision medicine in combating lung cancer. Our state-of-the-art assay and comprehensive biomarker landscape provide unparalleled insights into this devastating disease, empowering researchers, translational scientists, and bio-pharma companies to make informed decisions and advance patient care.
Our platform offers a holistic approach to lung cancer research. From identifying novel biomarkers and assessing their clinical relevance to developing personalized treatment strategies.
Biomarkers & Assays - Lung Cancer
Benefit from the most complete biomarkers and assays landscape for Lung Cancer.
What we cover
Our inaugural Beacon Biomarkers & Assays offering focuses on lung cancer, covering all biomarkers, assays and clinical trials investigating targeted therapies within the lung cancer landscape.
From preclinical validation of biomarkers and assays to regulatory interactions and updates to clinical trial data, this module encapsulates everything you need to know about the lung cancer biomarker and assay space.
How we can help
Advance your lung cancer biomarker and assay development programs by:
- Understanding and benchmarking the different biomarker strategies used in clinical trialsand the various assays and associated protocols used to measure these biomarkers.
- Scour the lung cancer landscape for novel or established biomarkers and assaysand investigate the associated preclinical validation studies.
- Track developments across the regulatory landscapefor lung cancer biomarkers and assays.
- Stay on top of emerging trends and new developments with real-time updates and alerts, as well as in-depth monthly reports curated by our analyst team.
How Biomarkers & Assays works
Search the biomarker, assay and trial lung cancer landscape by over 30 unique search filters including:
- Biomarker biology and classification
- Assay platform technology
- Regulatory status
- Drug target and therapeutic class
- Disease stage and line of therapy
Customize your search strategy to give you the data you need for your research focus.
What our customers say
“[Biomarkers & Assays] is going to be a blockbuster in my opinion. It’s very valuable. There's no doubt about it… If I can delve into this information sooner rather than later before we write protocols and such, it's going to be amazing”
Senior Vice President
Multinational Biopharmaceutical Company
Our Lung Cancer Expert
Dasha Kaloujskaia, is the lead research analyst for Biomarkers & Assays related trials and assays in the Beacon team.
Related Content
Navigating the Liquid Biopsy Landscape and the Role of ctDNA in Lung Cancer Research
The 2023 Lung Cancer, Biomarkers & Assays Landscape Review
Liquid Biopsy Assays For ctDNA Detection Infographic
Interested in a tour? Contact us
For a tour of the Beacon Biomarkers & Assays database, please contact the team below.
About Beacon Biomarkers & Assays
The selection of biomarkers and assays is of utmost importance as it directly impacts the accuracy and efficacy of diagnostic and treatment strategies.
By carefully selecting appropriate biomarkers and assays, researchers can drive advancements in cancer care, leading to earlier detection, more precise diagnosis, targeted therapies, and improved patient outcomes. Beacon are here to support you in making these decisions with confidence through our encompassing database solution.
